Telix Pharmaceuticals names David Gill as Board Chair
Gill succeeds Dr. Mark Nelson, who had served as interim Chair and will stay on the board as a Non-Executive Director.
SEC filing
Latest
2 stories
Monday, August 31
Wednesday, August 19
Intercure files Form D covering equity issued for Botanico acquisition
Intercure Ltd. registered a new securities offering tied to a share and warrant transaction related to its acquisition of ISHI (Botanico Ltd.), with a first sale date of June 15, 2026.
SEC filing